SCHEMBL4559293

SCHEMBL4559293

COC(OC)(C(=O)NN1CCNCC1)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 1/20 0.45
ALDH1A1 P00352 3/20 0.41
HTT P42858 2/20 0.41
OPRD1 P41143 3/20 0.40
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
SIGMAR1 Q99720 1/20 0.39
MAPT P10636 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
POLB P06746 1/20 0.38
KCNN4 O15554 1/20 0.38
KDM4E B2RXH2 1/20 0.37
GNAI3 P08754 1/20 0.37
GNAO1 P09471 1/20 0.37
GNAI1 P63096 1/20 0.37
CHRM2 P08172 1/20 0.36
CHRM4 P08173 1/20 0.36
CHRM5 P08912 1/20 0.36
CHRM1 P11229 1/20 0.36
CHRM3 P20309 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1079999 0.81 ALDH1A1 (0.47) ALDH1A1HTTOPRD1KMT2AMEN1
SCHEMBL3256684 0.78 SIGMAR1 (0.41) ALDH1A1HTTOPRD1KMT2AMEN1
SCHEMBL6904745 0.71 CES1 (0.58) CES1ALDH1A1HTTKMT2AMEN1
SCHEMBL6497297 0.71 CES1 (0.58) CES1ALDH1A1HTTKMT2AMEN1
SCHEMBL4559299 0.70 OPRD1 (0.39) CES1ALDH1A1HTTOPRD1KMT2A
SCHEMBL717372 0.69 HTT (0.69) ALDH1A1HTTOPRD1SIGMAR1SMN1; SMN2
SCHEMBL23037743 0.69 LIPE (0.58) ALDH1A1KMT2ASIGMAR1MAPTPOLB
SCHEMBL2028141 0.68 CES1 (0.54) CES1ALDH1A1HTTKMT2AMEN1
SCHEMBL27915480 0.68 GNAI3 (0.45) ALDH1A1HTTSIGMAR1MAPTGNAI3
SCHEMBL5580542 0.68 CES1 (0.69) CES1ALDH1A1OPRD1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7501407-B2 Pyrimidine A2B selective antagonist compounds, their synthesis and use OSI PHARMACEUTICALS, INC. (US) 2009-03-10 US disclosed
US-6916804-B2 Pyrimidine A2b selective antagonist compounds, their synthesis and use OSI PHARMACEUTICALS, INC. (US) 2005-07-12 US disclosed
US-20050119271-A1 Pyrimidine A2B selective antagonist compounds, their synthesis and use OSI PHARMACEUTICALS, INC. 2005-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119271-A1 Pyrimidine A2B selective antagonist compounds, their synthesis and use ADORA2B, ADORA2A, ADORA3 CES1 1823/4885ALDH1A1 2146/4885HTT 1259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.